共 152 条
[1]
Bittner B(2018)Subcutaneous Administration of Biotherapeutics: an overview of current challenges and opportunities BioDrugs. 32 425-440
[2]
Richter W(2020)Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics J Control Release 321 475-482
[3]
Schmidt J(2018)Challenges and opportunities for the subcutaneous delivery of therapeutic proteins J Pharm Sci 107 1247-1260
[4]
Collins DS(2018)The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review Respir Res 19 154-677
[5]
Sanchez-Felix M(2019)Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma Blood. 134 668-60
[6]
Badkar AV(2019)Economic benefits of subcutaneous trastuzumab administration: a single institutional study from Karolinska University hospital in Sweden PLoS One 14 e0211783-180
[7]
Mrsny R(2013)Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency Transfus Med 23 55-1664
[8]
Turner MR(2015)The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives Facts Views Vis Obgyn 7 176-361
[9]
Balu-Iyer SV(2016)Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes Clin Ther 38 1653-131
[10]
Matucci A(2019)Mode of injection and treatment adherence: results of a survey characterizing the perspectives of health care providers and US women 18-45 years old Patient Prefer Adherence 13 351-1982